Zydus's Sugammadex Gets Final Nod From USFDA
Indian pharma giant Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Sugammadex Injection, a single-dose vial and US reference listed drug of Bridion Injection, the company said in an exchange filing on Friday.
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery.
The injection will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara. Sugammadex Injection had annual sales of USD 986 million in the United States (IQVIA MAT Aug 2023), the company informed.
